Health Care & Life Sciences » Biotechnology | Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
12,019.00
122,045.00
147,465.00
215,003.00
302,238.00
408,897
Cost of Goods Sold (COGS) incl. D&A
1,104.00
5,758.00
8,423.00
11,986.00
15,215.00
15,356
Gross Income
10,915.00
116,287.00
139,042.00
203,017.00
287,023.00
393,541
SG&A Expense
72,835.00
92,057.00
118,198.00
148,801.00
187,482.00
249,097
EBIT
61,920.00
24,230.00
-
54,216.00
99,541.00
144,444
Unusual Expense
22,904.00
217.00
2,145.00
223.00
219.00
-
Non Operating Income/Expense
101.00
39.00
38.00
15.00
-
-
Interest Expense
7,849.00
4,963.00
4,770.00
5,091.00
1,568.00
18,111
Pretax Income
92,273.00
19,871.00
14,610.00
50,369.00
100,618.00
140,176
Income Tax
-
-
666.00
40,852.00
43,334.00
29,183
Consolidated Net Income
92,273.00
19,871.00
13,944.00
91,221.00
57,284.00
110,993
Net Income
92,273.00
19,871.00
13,944.00
91,221.00
57,284.00
110,993
Net Income After Extraordinaries
92,273.00
19,871.00
13,944.00
91,221.00
57,284.00
110,993
Net Income Available to Common
92,273.00
19,871.00
13,944.00
91,221.00
57,284.00
110,993
EPS (Basic)
2.90
0.32
0.28
1.76
1.08
2.05
Basic Shares Outstanding
31,848.30
42,260.90
47,485.30
49,472.40
50,756.60
51,989.80
EPS (Diluted)
2.90
0.32
0.28
1.76
1.08
2.05
Diluted Shares Outstanding
31,848.30
50,583.50
51,160.40
51,709.00
53,301.20
54,098.90
EBITDA
61,178.00
25,158.00
21,765.00
56,615.00
107,673.00
151,507
Non-Operating Interest Income
299.00
348.00
643.00
1,482.00
2,864.00
13,843

About Supernus Pharmaceuticals

View Profile
Address
1550 East Gude Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.supernus.com
Updated 07/08/2019
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.